CUBT

Curative Biotechnology, Inc.

Price Chart

Latest Quote

$0.83

-0.00 (-0.06%)

Current Price

Previous Close	$0.83
Open	$0.69
Day High	$0.83
Day Low	$0.69
Volume	717

Fetched: 2026-10-31T03:41:53

Stock Information

Shares Outstanding	8.89M
Net Income	$-2.84M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.38M
EPS (TTM)	$-0.44
Exchange	OID

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Income	$-2.84M
Book/sh	$-0.80

Financial Ratios

Quick Ratio	0.00
Current Ratio	0.01

Returns & Margins

Ownership

Insider Ownership	0.04%
Insider & Institutional transactions data not available

Valuation Ratios

P/B

-1.04

Analyst Data

Recommendation

none

Technical Indicators

SMA20	$0.89
SMA50	$0.92
SMA200	$1.11
RSI	37.53
ATR	0.1403

Shares Float	4.91M
Volatility	1.30
Rel Volume	0.67

Performance History

Week	+16.16%
Month	-10.74%
Quarter	-43.96%
6 Months	-12.69%
YTD	+11.70%
Year	-21.01%
3 Years	-43.58%
5 Years	-94.47%
10 Years	+2664.76%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-10-29	$0.83	1,076
2026-10-28	$0.83	300
2026-10-27	$0.83	809
2026-10-26	$0.79	1,200
2026-10-23	$0.70	200
2026-10-22	$0.71	104
2026-10-21	$0.71	7,353
2026-10-20	$0.91	1,712
2026-10-19	$0.91	300
2026-10-16	$0.91	342
2026-10-15	$0.95	200
2026-10-14	$0.90	7,100
2026-10-13	$0.95	600
2026-10-12	$0.95	0
2026-10-09	$0.95	4,879
2026-10-08	$1.00	274
2026-10-07	$1.25	5,074
2026-10-06	$0.92	200
2026-10-05	$0.80	200
2026-10-02	$0.93	0
2026-10-01	$0.93	0
2026-09-30	$0.93	0

About Curative Biotechnology, Inc.

Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.

📰 Latest News

No news articles available at the moment. Check back later for updates on CUBT.

Period:

Income Statement (Annual)

Metric	2022-12-31	2021-12-31
Revenue
Reconciled Cost Of Revenue	$0	$0
Cost Of Revenue	$0	$0
Total Revenue	$0	$0
Operating Revenue	$0	$0
Expenses
Interest Expense	$1,170,319	$176,672
Total Expenses	$4,435,688	$4,997,374
Other Income Expense	$1,114	$-166,308
Other Non Operating Income Expenses	$4,914	-
Net Non Operating Interest Income Expense	$-1,170,319	$-176,672
Interest Expense Non Operating	$1,170,319	$176,672
Operating Expense	$4,435,688	$4,997,374
General And Administrative Expense	$1,945,653	$4,211,355
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-5,604,893	$-5,340,354
Net Interest Income	$-1,170,319	$-176,672
Normalized Income	$-5,601,093	$-5,174,046
Net Income From Continuing And Discontinued Operation	$-5,604,893	$-5,340,354
Total Operating Income As Reported	$-4,439,488	$-5,014,332
Net Income Common Stockholders	$-5,604,893	$-5,340,354
Net Income	$-5,604,893	$-5,340,354
Net Income Including Noncontrolling Interests	$-5,604,893	$-5,340,354
Net Income Continuous Operations	$-5,604,893	$-5,340,354
Pretax Income	$-5,604,893	$-5,340,354
Special Income Charges	$-3,800	$-166,308
Operating Income	$-4,435,688	$-4,997,374
Depreciation Amortization Depletion Income Statement	$7,956	$6,744
Depreciation And Amortization In Income Statement	$7,956	$6,744
Gross Profit	$0	$0
Per Share
Diluted EPS	$-0.01	$-0.01
Basic EPS	$-0.01	$-0.01
Other
Tax Effect Of Unusual Items	$0	$0
Tax Rate For Calcs	$0	$0
Normalized EBITDA (Bullshit earnings)	$-4,422,818	$-4,990,630
Total Unusual Items	$-3,800	$-166,308
Total Unusual Items Excluding Goodwill	$-3,800	$-166,308
Reconciled Depreciation	$7,956	$6,744
EBITDA (Bullshit earnings)	$-4,426,618	$-5,156,938
EBIT	$-4,434,574	$-5,163,682
Diluted Average Shares	$572,009,911	$3,402,157
Basic Average Shares	$572,009,911	$3,402,157
Diluted NI Availto Com Stockholders	$-5,604,893	$-5,340,354
Impairment Of Capital Assets	$3,800	$16,958
Research And Development	$2,482,079	$779,275
Selling General And Administration	$1,945,653	$4,211,355
Other Gand A	$1,945,653	$4,211,355
Other Special Charges	-	$149,350

Fetched: 2026-02-02

Balance Sheet (Annual)

Metric	2022-12-31	2021-12-31
Assets
Net Tangible Assets	$-22,153,892	$-17,920,292
Total Assets	$2,089,191	$2,412,150
Total Non Current Assets	$2,020,523	$1,658,245
Non Current Deferred Assets	$390,104	$92,975
Goodwill And Other Intangible Assets	$1,624,155	$1,558,550
Current Assets	$68,668	$753,905
Prepaid Assets	$10,000	$58,642
Receivables	$0	$25,000
Cash Cash Equivalents And Short Term Investments	$58,668	$670,263
Cash And Cash Equivalents	$58,668	$670,263
Cash Financial	$58,668	$670,263
Other Receivables	-	$25,000
Debt
Net Debt	$1,011,980	-
Total Debt	$1,070,648	-
Current Debt And Capital Lease Obligation	$1,070,648	-
Current Debt	$1,070,648	-
Other Current Borrowings	$870,648	-
Liabilities
Total Liabilities Net Minority Interest	$22,618,928	$18,773,892
Total Non Current Liabilities Net Minority Interest	$18,131,825	$18,043,557
Current Liabilities	$4,487,103	$730,335
Other Current Liabilities	$21,911	$3,431
Current Notes Payable	$200,000	$0
Payables And Accrued Expenses	$3,394,544	$726,904
Equity
Common Stock Equity	$-20,529,757	$-16,361,750
Preferred Stock Equity	$20	$8
Total Equity Gross Minority Interest	$-20,529,737	$-16,361,742
Stockholders Equity	$-20,529,737	$-16,361,742
Retained Earnings	$-32,610,198	$-26,917,036
Preferred Securities Outside Stock Equity	$18,131,825	$18,043,557
Other
Ordinary Shares Number	$579,271,135	$537,881,194
Share Issued	$579,271,135	$537,881,194
Tangible Book Value	$-22,153,912	$-17,920,300
Invested Capital	$-19,459,109	$-16,361,750
Working Capital	$-4,418,435	$23,570
Total Capitalization	$-20,529,737	$-16,361,742
Additional Paid In Capital	$12,022,514	$10,498,221
Capital Stock	$57,947	$57,073
Common Stock	$57,927	$57,065
Preferred Stock	$20	$8
Net PPE	$6,264	$6,720
Accumulated Depreciation	$-570	$-114
Gross PPE	$6,834	$6,834

Fetched: 2026-02-02

Cash Flow Statement (Annual)

Metric	2022-12-31	2021-12-31
Free Cash Flow
Free Cash Flow	$-1,612,478	$-1,625,369
Operating Activities
Operating Cash Flow	$-1,535,573	$-1,604,035
Cash Flow From Continuing Operating Activities	$-1,535,573	$-1,604,035
Operating Gains Losses	-	$149,350
Investing Activities
Capital Expenditure	$-76,905	$-21,334
Investing Cash Flow	$-76,905	$-21,334
Cash Flow From Continuing Investing Activities	$-76,905	$-21,334
Financing Activities
Issuance Of Capital Stock	$116,000	$1,573,000
Financing Cash Flow	$1,000,883	$2,065,025
Cash Flow From Continuing Financing Activities	$1,000,883	$2,065,025
Net Other Financing Charges	$-250,779	$-92,975
Net Preferred Stock Issuance	$116,000	$0
Preferred Stock Issuance	$116,000	$0
Net Common Stock Issuance	$0	$1,573,000
Common Stock Issuance	$0	$1,573,000
Other
Repayment Of Debt	$-86,700	$-50,000
Issuance Of Debt	$1,069,972	$110,000
Interest Paid Supplemental Data	$124,886	$10,000
Income Tax Paid Supplemental Data	$0	$0
End Cash Position	$58,668	$600,263
Beginning Cash Position	$670,263	$160,607
Changes In Cash	$-611,595	$439,656
Proceeds From Stock Option Exercised	$152,390	$525,000
Net Issuance Payments Of Debt	$983,272	$60,000
Net Short Term Debt Issuance	$983,272	$60,000
Short Term Debt Payments	$-86,700	$-50,000
Short Term Debt Issuance	$1,069,972	$110,000
Net Intangibles Purchase And Sale	$-76,905	$-14,500
Purchase Of Intangibles	$-76,905	$-14,500
Net PPE Purchase And Sale	$0	$-6,834
Purchase Of PPE	$0	$-6,834
Change In Working Capital	$2,741,282	$549,026
Change In Payables And Accrued Expense	$2,667,640	$592,320
Change In Prepaid Assets	$48,642	$-18,294
Change In Receivables	$25,000	$-25,000
Other Non Cash Items	$1,037,478	$124,674
Stock Based Compensation	$278,804	$2,889,567
Asset Impairment Charge	$3,800	$16,958
Depreciation Amortization Depletion	$7,956	$6,744
Depreciation And Amortization	$7,956	$6,744
Net Income From Continuing Operations	$-5,604,893	$-5,340,354

Fetched: 2026-02-02